artificial intelligence system
DeviceUse artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound
Other names: Artificial Intelligence
NCT Number: NCT07251114
This study mainly uses an artificial intelligence system to assist in the classification of the depth of invasion of early esophageal squamous cell carcinoma under ultrasound endoscopy, providing a basis for preoperative T staging and diagnosis and treatment decisions.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Fujian provincial hospital, Fuzhou, Fujian, China
For patients with early esophageal squamous cell carcinoma and precancerous lesions who met the inclusion and exclusion criteria and voluntarily participated in this project, they were randomly divided into the AI group and the conventional group by central randomization, with 100 cases in each group(anticipated). Randomization method: The personnel responsible for randomization at the center (who do not participate in the inclusion of subjects) log in to the central randomization system to obtain a randomization number, and finally form a randomization allocation table. Blinding implementation: The observation group and control group determined on the random allocation table were marked as A and B respectively, and then the operating physician implemented protocol A or B. Main indicators: Grading judgment of infiltration depth, pathological consistency
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use artificial intelligence to assist in the determination of the invasion depth of early esophageal squamous cell carcinoma under endoscopic ultrasound
Other names: Artificial Intelligence
Time frame: 2 years
By comparing with the postoperative pathology, the accuracy of the preoperative T grading with the assistance of the artificial intelligence grading system was verified
Time frame: Three years
3-year survival rate
Time frame: 1 year
The period from the start of treatment to tumor progression or death for any reason
Contact information is provided by the study sponsor or research team.
Wei Liang, MD
CONTACT
Yanqin Xu, MD
CONTACT
Fujian Provincial Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06381583
Adenocarcinoma Of Esophagus, Barrett Adenocarcinoma
Duarte, California, United States
View Trial DetailsNCT06515964
Digestive System Diseases, Digestive System Neoplasms
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT02366039
Barrett's Esophagus With High Grade Dsyplasia, Digestive System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT06906887
Digestive System Diseases, Digestive System Neoplasms
Milwaukee, Wisconsin, United States
View Trial Details